Oruka Therapeutics ORKA
NASDAQ ORKA
$84.52 +1.10 (+1.32%)
At close: Oct 2, 2026 · 4:00 PM EDT

Oruka Therapeutics (ORKA) Gains from Sales and Divestitures (2011 - 2022)

Updated

Oruka Therapeutics (ORKA) posted Gains from Sales and Divestitures of -$5,000 for FY2022.

Analysis

Oruka Therapeutics (ORKA) Gains from Sales and Divestitures (2011 - 2022) Analysis & Trends

  • The FY2022 figure stands as the highest annual Gains from Sales and Divestitures since FY2010.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Oruka Therapeutics 5.31 Bn 3.37 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 -3,000.00
Mar 31, 2022 -2,000.00
Dec 31, 2011 -12,000.00
Sep 30, 2011 1,000.00
Mar 31, 2011 -5,000.00
API Access

Oruka Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ORKA&period=max&api_key=YOUR_API_KEY